Search Results - "Ventriglia, María Verónica"

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy by Sanchez, María Belén, Vasconcelos Cordoba, Bianca, Pavlovsky, Carolina, Moiraghi, Beatriz, Varela, Ana, Custidiano, Rosario, Fernandez, Isolda, Freitas, María Josefina, Ventriglia, María Verónica, Bendek, Georgina, Mariano, Romina, Mela Osorio, María José, Pavlovsky, Miguel Arturo, García de Labanca, Ana, Foncuberta, Cecilia, Giere, Isabel, Vera, Masiel, Juni, Mariana, Mordoh, José, Sanchez Avalos, Julio Cesar, Levy, Estrella Mariel, Bianchini, Michele

“…Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase is considered a safe option if suitable molecular monitoring is…”
Get full text

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal by Pavlovsky, Carolina, Vasconcelos Cordoba, Bianca, Sanchez, María Belén, Moiraghi, Beatriz, Varela, Ana, Custidiano, Rosario, Fernandez, Isolda, Freitas, Maria Josefina, Ventriglia, Maria Verónica, Bendek, Georgina, Mariano, Romina, Mela Osorio, María José, Pavlovsky, Miguel Angel, de Labanca, Ana García, Foncuberta, Cecilia, Giere, Isabel, Vera, Masiel, Juni, Mariana, Mordoh, Jose, Sanchez Avalos, Julio Cesar, Cueto, Gerardo, Miranda, Silvia, Levy, Estrella Mariel, Bianchini, Michele

“…Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may…”
Get full text

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina by Varela, Ana Inés, Penalba, Romina Laura, Enrico, Alicia, Catalan, Marta, Ventriglia, Maria Veronica, Freitas, Maria Josefina, Pavlovsky, Carolina, Garbiero, Susana, Beccasese, Martin, Bengio, Raquel Maria Nelida, Abramovich, Catalina, Pavlovsky, Miguel A, Moiraghi, Elena Beatriz

“…INTRODUCTION: Ponatinib is a potent TKI indicated in T315I mutated CML and not mutated CML resistant to other drugs. Deep responses were reported in PACE trial…”
Get full text